risks of glp-1 medications receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing kidney failure. Adverse events are mostly gastrointestinal glp 1 drugs risks GLP-1

Peptides fortify conventional tools against plateaus, with some users reporting 50 percent faster reductions in shedding when stacking treatments

However, most of the subjects included in the RCTs are PCOS patients with obesity/overweight, whereas a portion of PCOS women, which can even reach 50%, might present a lean phenotype

Prune consumption attenuates proinflammatory cytokine secretion and alters monocyte activation in postmenopausal women: secondary outcome analysis of a 12-mo randomized controlled trial: the prune study

July 24, 2025 Consumer trends research by Innova Market Insights shows that consumers globally are more concerned about weight management that about other physical health issues